All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @imajacobcracker on TikTok · 33s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @imajacobcracker's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I tell myself, don't leave a pain
  2. 0:06A lumpy dot, that you'll hold on me
  3. 0:08It ain't even putting in my face
  4. 0:11I just crumble
  5. 0:13I tell myself, I don't get a blow
  6. 0:16I tell the guy, tell the kid I'll kill
  7. 0:18I'll kill you
  8. 0:20I'm the nothing that I need
  9. 0:24I'm the nothing that I need
  10. 0:27A lumpy dot, that you'll kill
  11. 0:30I'm the nothing that I need

TikTok creator shares Tostran gel experience, here's the science

jay

TikTok creator

8.8K viewsWatch on TikTok

Quick answer

The creator references using Tostran, a 2% testosterone gel licensed for hypogonadism in the UK and EU, and notes individual variation in treatment response. This is pharmacologically accurate: transdermal testosterone absorption varies significantly between patients due to skin characteristics, application site, and body composition. Clinical guidelines require regular serum testosterone monitoring to confirm therapeutic levels, as symptomatic response alone is insufficient to guide dosing.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TikTok creator shares Tostran gel experience, here's the science, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

TikTok creator shares Tostran gel experience, here's the science is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TikTok creator shares Tostran gel experience, here's the science" from jay. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator references using Tostran, a 2% testosterone gel licensed for hypogonadism in the UK and EU, and notes individual variation in treatment response.

The reason this review is not generic is the source wording and the canonical claim label "trt ignore the flex and terrible dance i m on tostran gel and." In this clip, the useful excerpt is: "I tell myself, don't leave a pain A lumpy dot, that you'll hold on me It ain't even putting in my face I just crumble I tell myself, I don't get a blow I tell the guy, tell the kid I'll kill I'll kill you I'm the nothing that I need I'm..." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Transdermal testosterone absorption varies significantly between individuals: Wang et al.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator references using Tostran, a 2% testosterone gel licensed for hypogonadism in the UK and EU, and notes individual variation in treatment response.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator references using Tostran, a 2% testosterone gel licensed for hypogonadism in the UK and EU, and notes individual variation in treatment response. This is pharmacologically accurate: transdermal testosterone absorption varies significantly between patients due to skin characteristics, application site, and body composition. Clinical guidelines require regular serum testosterone monitoring to confirm therapeutic levels, as symptomatic response alone is insufficient to guide dosing.
  • Tostran is a licensed 2% testosterone gel available in the UK for diagnosed hypogonadism, not an over-the-counter supplement.
  • Transdermal testosterone absorption varies significantly between individuals: Wang et al. (2004, JCEM) confirmed this is a pharmacokinetic reality, not just subjective perception.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Tostran is a licensed 2% testosterone gel available in the UK for diagnosed hypogonadism, not an over-the-counter supplement.
  • Transdermal testosterone absorption varies significantly between individuals: Wang et al. (2004, JCEM) confirmed this is a pharmacokinetic reality, not just subjective perception.
  • The FDA issued a black box warning on testosterone gels in 2009 due to documented virilisation in children from secondary skin contact with treated adults.
  • Symptom tracking alone cannot confirm whether gel treatment is effective. Serum testosterone blood tests are required, typically 2-4 hours post-application for gel formulations.
  • Application site affects absorption: Rogenfeld et al. (2011, European Journal of Endocrinology) found measurable differences between thigh and shoulder application pharmacokinetics.
  • The Endocrine Society (Bhasin et al., 2018 clinical practice guidelines) recommends titrating gel dose based on blood levels, not symptom response alone.
  • This video makes no dangerous or inaccurate medical claims, but omits secondary transfer risk, which is a significant real-world safety consideration for anyone using testosterone gels.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @imajacobcracker actually say?

Honestly? Almost nothing medically specific. The transcript appears to be song lyrics, likely Paloma Faith based on the caption hashtag, playing over footage of the creator. The one substantive claim is buried in the caption, not the spoken content: the creator is using Tostran gel for TRT and says "everyone's transition is different." That's the entire medical claim on the table. Everything else is a dance and a vibe.

This matters because fact-checking a TikTok where the clinical content lives in a caption rather than the spoken word is frustrating but not uncommon. What we can assess is the implicit claim: that Tostran gel is a legitimate TRT option, that individual responses vary, and that sharing personal experience has value. Those are the things worth examining.

Does the science back this up?

On the variability point, yes, fully. Inter-individual variation in testosterone gel absorption is one of the more robustly documented phenomena in endocrinology. The short answer is that skin matters enormously, and two people applying the same dose get meaningfully different serum levels.

Tostran is a 2% testosterone gel licensed in the UK and several EU countries. A pharmacokinetic study by Wang et al. (2004, Journal of Clinical Endocrinology and Metabolism) established that transdermal testosterone produces significant variability in serum T levels between patients, with some individuals absorbing far less than expected. A later analysis by Bhasin et al. (2010, Journal of Clinical Endocrinology and Metabolism) confirmed that factors including application site, skin hydration, body hair density, and scrotal versus non-scrotal application all shift absorption meaningfully. So "everyone's transition is different" is not just a feel-good disclaimer, it is pharmacologically accurate.

What did they get wrong (or right)?

They got the core message right. Individual variation in TRT response is real and frequently underappreciated by patients who benchmark their progress against online forums or other users. The creator deserves credit for not making specific dosing claims, not promising outcomes, and framing this explicitly as personal experience.

What is absent is any meaningful clinical context. There is no mention of blood monitoring, no acknowledgment that absorption site matters, no reference to the transfer risk Tostran carries to partners or children through skin contact. The Endocrine Society's 2018 clinical practice guidelines (Bhasin et al., Journal of Clinical Endocrinology and Metabolism) explicitly flag secondary exposure as a patient education priority. That omission is not a lie, but it is a gap. Gel-based testosterone carries real secondary exposure risk, and a video reaching 8,800 people with no mention of this is a missed opportunity at minimum.

What should you actually know?

If you are considering or already using a testosterone gel like Tostran, a few things matter that this video does not cover.

  • Absorption is genuinely unpredictable. Regular blood tests are not optional. Symptom tracking alone is not sufficient to assess whether your treatment is working or whether your levels are in a therapeutic range.
  • Application site affects outcomes. Inner thigh application, which Tostran specifically licences, tends to produce different pharmacokinetics than upper arm or shoulder application used by other gel formulations. Study: Rogenfeld et al. (2011, European Journal of Endocrinology) found thigh application produced comparable but distinct absorption curves versus shoulder sites.
  • Secondary transfer is a documented safety concern. The FDA issued a black box warning on testosterone gels in 2009 specifically because of virilisation cases in children exposed through skin contact with treated adults. Wash hands, cover the application site, and do not allow partners or children to contact untreated skin.
  • "Everyone's transition is different" is accurate but should not be used to delay investigating why treatment is not working. If you are not seeing expected results after three to six months of consistent use, that warrants clinical review, not more patience.

The bottom line

This video is essentially a personal update with a single accurate observation buried in the caption. The creator is not making dangerous claims. They are not prescribing doses, promising outcomes, or selling anything. The implicit message, that testosterone gel works differently for different people, is supported by the literature. The gaps are around secondary exposure and the necessity of monitoring, which are genuinely important and absent. As TRT content goes, this is benign. It is also thin on actual information.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

jay · TikTok creator

8.8K views on this video

Ignore the flex and terrible dance 🥴 I’m on Tostran gel and everyone’s transition is different but if this helps 1 person, I’ll settle for that :) #imajacobcracker #fyp #4u #foryoupage #foryourmumspa

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tostran?

Tostran is a licensed 2% testosterone gel available in the UK for diagnosed hypogonadism, not an over-the-counter supplement.

What does the video say about transdermal testosterone absorption varies significantly between individuals: wang et al.?

Transdermal testosterone absorption varies significantly between individuals: Wang et al. (2004, JCEM) confirmed this is a pharmacokinetic reality, not just subjective perception.

What does the video say about the fda?

The FDA issued a black box warning on testosterone gels in 2009 due to documented virilisation in children from secondary skin contact with treated adults.

What does the video say about symptom tracking alone cannot confirm whether gel treatment?

Symptom tracking alone cannot confirm whether gel treatment is effective. Serum testosterone blood tests are required, typically 2-4 hours post-application for gel formulations.

What does the video say about application site affects absorption: rogenfeld et al. (2011, european journal?

Application site affects absorption: Rogenfeld et al. (2011, European Journal of Endocrinology) found measurable differences between thigh and shoulder application pharmacokinetics.

What does the video say about the endocrine society (bhasin et al., 2018 clinical practice guidelines)?

The Endocrine Society (Bhasin et al., 2018 clinical practice guidelines) recommends titrating gel dose based on blood levels, not symptom response alone.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by jay, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.